IFNG and neoplasm: Other factors contributing to this resistance include the lack of effective neoantigens in tumours, impaired tumour antigen presentation, inadequate infiltration of immune cells into the tumour, compromised interferon‐gamma (IFN‐γ) signalling, metabolic and inflammatory mediators, immunosuppressive cells, altered immune checkpoints, severe T‐cell exhaustion and epigenetic alterations in T cells.4